J-STAR Research, Inc.

jstar-research.com

J-STAR Research
J-STAR Research, Inc. is a contract chemistry organization serving as an outsourcing partner for the pharmaceutical and biotechnology industries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

VIEWS AND ANALYSIS, PHARMA TECH

VIRPAX PHARMACEUTICALS REPORTS ON FDA PRE-IND RESPONSE FOR NOBRXIOL™ (FORMERLY VRP324)

Virpax Pharmaceuticals | December 15, 2022

news image

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and viral barrier indications, today announced that it has received pre-Investigational New Drug application guidance from the U.S. Food and Drug Administration for NobrXiol™, the Company’s product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utili...

Read More

BIG PHARMA RETURNING TO U.S. PRICE HIKES IN JANUARY AFTER PAUSE

Reuters: | February 19, 2020

news image

Novartis AG (NOVN.S) and Bayer AG (BAYGn.DE) are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters. Other drugmakers set to raise prices at the start of 2019 include Allergan Plc (AGN.N), GlaxoSmithKline Plc (GSK.L), Amgen Inc (AMGN.O), AstraZeneca Plc (AZN.L) and Biogen Inc (BIIB.O), the doc...

Read More

GILEAD CLIMBS AS CORONAVIRUS DRUG SHOWS EFFICACY, STARTS TRIAL

FierceBiotech | February 03, 2020

news image

Gilead has made progress in its effort to reposition failed Ebola drug remdesivir as a treatment for the coronavirus sweeping across China. In quick succession, it emerged that the nucleotide analogue prodrug appeared to help the first U.S. case of the virus and is set to undergo clinical testing in China, sending Gilead’s stock up by as much as 13% in premarket trading. Remdesivir was one of a clutch of drugs tested against Ebola, but it failed to match the efficacy of its rivals, leading...

Read More

GILEAD JOINS GSK, J&J IN OFFERING CORONAVIRUS VACCINE OPTIONS

PharmaTimes | February 05, 2020

news image

With the death toll in China topping 425, the coronavirus, now officially classified as a global health threat by the World Health Organisation (WHO), is showing no signs of slowing down. More than 20,000 cases have been confirmed around the world, with more than 20 nations reporting cases – some involving locals who had not even travelled to China. The pharma industry has been rallying together in a joint effort to develop a vaccine for the virus, which is also known as 2019-nCoV or Wuhan...

Read More
news image

VIEWS AND ANALYSIS, PHARMA TECH

VIRPAX PHARMACEUTICALS REPORTS ON FDA PRE-IND RESPONSE FOR NOBRXIOL™ (FORMERLY VRP324)

Virpax Pharmaceuticals | December 15, 2022

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and viral barrier indications, today announced that it has received pre-Investigational New Drug application guidance from the U.S. Food and Drug Administration for NobrXiol™, the Company’s product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utili...

Read More
news image

BIG PHARMA RETURNING TO U.S. PRICE HIKES IN JANUARY AFTER PAUSE

Reuters: | February 19, 2020

Novartis AG (NOVN.S) and Bayer AG (BAYGn.DE) are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters. Other drugmakers set to raise prices at the start of 2019 include Allergan Plc (AGN.N), GlaxoSmithKline Plc (GSK.L), Amgen Inc (AMGN.O), AstraZeneca Plc (AZN.L) and Biogen Inc (BIIB.O), the doc...

Read More
news image

GILEAD CLIMBS AS CORONAVIRUS DRUG SHOWS EFFICACY, STARTS TRIAL

FierceBiotech | February 03, 2020

Gilead has made progress in its effort to reposition failed Ebola drug remdesivir as a treatment for the coronavirus sweeping across China. In quick succession, it emerged that the nucleotide analogue prodrug appeared to help the first U.S. case of the virus and is set to undergo clinical testing in China, sending Gilead’s stock up by as much as 13% in premarket trading. Remdesivir was one of a clutch of drugs tested against Ebola, but it failed to match the efficacy of its rivals, leading...

Read More
news image

GILEAD JOINS GSK, J&J IN OFFERING CORONAVIRUS VACCINE OPTIONS

PharmaTimes | February 05, 2020

With the death toll in China topping 425, the coronavirus, now officially classified as a global health threat by the World Health Organisation (WHO), is showing no signs of slowing down. More than 20,000 cases have been confirmed around the world, with more than 20 nations reporting cases – some involving locals who had not even travelled to China. The pharma industry has been rallying together in a joint effort to develop a vaccine for the virus, which is also known as 2019-nCoV or Wuhan...

Read More